Cargando…
Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives
Coronavirus disease 2019 (COVID-19) is a potentially fatal disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that preferentially infects the respiratory tract. Bradykinin (BK) is a hypotensive substance that recently emerged as one of the mechanisms to explain COVID-...
Autores principales: | da Silva, Manuele Figueiredo, de Araújo-Júnior, João Xavier, da Silva-Júnior, Edeildo Ferreira, Heimfarth, Luana, Martins-Filho, Paulo Ricardo, Quintans, Jullyana de Souza Siqueira, Quintans-Júnior, Lucindo José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795307/ https://www.ncbi.nlm.nih.gov/pubmed/35089406 http://dx.doi.org/10.1007/s00210-022-02206-6 |
Ejemplares similares
-
Drug repurposing and cytokine management in response to COVID-19: A review
por: Heimfarth, Luana, et al.
Publicado: (2020) -
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
por: Martins-Filho, Paulo Ricardo, et al.
Publicado: (2021) -
Cyclodextrin–Drug Inclusion Complexes: In Vivo and In Vitro Approaches
por: Carneiro, Simone Braga, et al.
Publicado: (2019) -
Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity
por: Rocha Santos Passos, Fabiolla, et al.
Publicado: (2022) -
Ivermectin: Panacea or true promise for COVID-19
por: Heimfarth, Luana, et al.
Publicado: (2020)